Selection of the optimal patient-specific therapeutic pathway depends on the BP phenotype, the presence of BCR::ABL1 kinase domain mutations, previous therapy for secondary CML-BP, and the availability of suitable stem cell donors. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.